Which peptides are on FDA’s compounding safety-risk list?

Short answer

FDA’s page of bulk substances that may present significant safety risks in compounding lists 20 of the substances profiled here: AOD-9604, BPC-157, CJC-1295, Dihexa, Emideltide, Epitalon, GHK-Cu, GHRP-2, GHRP-6, Ipamorelin, Kisspeptin-10, KPV, LL-37, Melanotan II, MK-677, PEG-MGF, Selank, Semax, TB-500 and Thymosin alpha-1.1 Some are listed in category 2 and others among nominations that were withdrawn; each row quotes its profile.

Each entry below quotes its profile and links to the full answer there.

Listed 20

Profiles that say the page does not list them 29

Profiles that do not say whether the current page lists them 1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    FDA briefing document for BPC-157-related bulk drug substances ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗

    U.S. Department of Justice · Official source · Source checked July 22, 2026

  6. 6
    FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026

  7. 7
    FDA briefing document for epitalon ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  9. 9
    FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  10. 10
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    FDA briefing document for KPV ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  12. 12
    Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  13. 13
    FDA briefing document for Semax ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  14. 14
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  15. 15
    FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  16. 16
    5-Amino-1-methylquinolinium substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  17. 17
    Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  18. 18
    Apraglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  19. 19
    STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure (2026) · PMID 42692160 ↗

    Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026

  20. 20
    Avexitide acetate substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  21. 21
    PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026

  22. 22
    Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗

    Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026

  23. 23
    Aviptadil substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  24. 24
    Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (2023) · PMID 37348524 ↗

    The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026

  25. 25
    Cerebrolysin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  26. 26
    Cibinetide (ARA 290) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  27. 27
    Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (2017) · PMID 28475703 ↗

    Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026

  28. 28
    Cotadutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  29. 29
    Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗

    Diabetes Care · Official source · Source checked November 15, 2026

  30. 30
    Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  31. 31
    ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  32. 32
    Efinopegdutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  33. 33
    Efpeglenatide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  34. 34
    ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  35. 35
    Eloralintide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  36. 36
    Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗

    The Lancet · Official source · Source checked November 15, 2026

  37. 37
    Drugs@FDA: FUZEON (enfuvirtide), NDA 021481 · original approval March 13, 2003 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  38. 38
    Follistatin (activin-binding protein) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  39. 39
    Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (2017) · PMID 28340339 ↗

    Cell · Official source · Source checked November 16, 2026

  40. 40
    Glepaglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  41. 41
    Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗

    Gastroenterology · Official source · Source checked November 15, 2026

  42. 42
    Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  43. 43
    Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  44. 44
    Examorelin (hexarelin) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  45. 45
    Humanin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  46. 46
    Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  47. 47
    Larazotide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  48. 48
    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (2015) · PMID 25683116 ↗

    Gastroenterology · Official source · Source checked November 15, 2026

  49. 49
    Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications (May 14, 2020) · FR Doc. 2020-10367 ↗

    Federal Register · Official source · Source checked November 15, 2026

  50. 50
    Drugs@FDA: NATRECOR (nesiritide), NDA 020920 · original approval August 10, 2001 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  51. 51
    Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection (February 13, 2019) · FR Doc. 2019-02146 ↗

    Federal Register · Official source · Source checked November 16, 2026

  52. 52
    Drugs@FDA: OMONTYS (peginesatide acetate), NDA 202799 · original approval March 27, 2012 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  53. 53
    Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗

    Federal Register · Official source · Source checked November 15, 2026

  54. 54
    Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  55. 55
    SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  56. 56
    Tesofensine substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  57. 57
    Thymopentin substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  58. 58
    Thymosin beta-4 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  59. 59
    Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗

    Obesity · Official source · Source checked November 16, 2026

  60. 60
    ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  61. 61
    FDA briefing document for MOTS-c ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  62. 62
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026